Komura K, Yanaba K, Ogawa F, Shimizu K, Takehara K, Sato S
Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Clin Exp Dermatol. 2008 May;33(3):329-32. doi: 10.1111/j.1365-2230.2007.02678.x. Epub 2008 Feb 28.
It is unclear whether any clinical and laboratory features are associated with pulmonary fibrosis (PF) in systemic sclerosis (SSc). We assessed these features using a database of 29 patients with SSc and anti-topoisomerase I antibodies and 68 patients with SSc and anticentromere antibody (ACA). Clinical features were not associated with the incidence of PF in patients with SSc and anti-topoisomerase I antibodies, although severe skin sclerosis was correlated with the presence of PF in patients with ACA. Serum IgG levels were often raised in patients with SSc and PF. Serum IgG levels in patients with PF were significantly higher than those in patients without PF, and were negatively correlated with percentage vital capacity and percentage diffusing capacity of the lung for carbon monoxide. In addition, serum IgG levels were correlated with serum interleukin-6. Thus, serum IgG levels are associated with PF in patients with SSc and anti-topoisomerase I antibodies and in patients with SSc and ACA.
目前尚不清楚系统性硬化症（SSc）中的任何临床和实验室特征是否与肺纤维化（PF）相关。我们使用一个包含29例抗拓扑异构酶I抗体的SSc患者和68例抗着丝点抗体（ACA）的SSc患者的数据库评估了这些特征。临床特征与抗拓扑异构酶I抗体的SSc患者中PF的发生率无关，尽管严重皮肤硬化与ACA患者中PF的存在相关。SSc和PF患者的血清IgG水平常升高。PF患者的血清IgG水平显著高于无PF患者，且与肺活量百分比和肺一氧化碳弥散百分比呈负相关。此外，血清IgG水平与血清白细胞介素-6相关。因此，血清IgG水平与抗拓扑异构酶I抗体的SSc患者以及ACA的SSc患者中的PF相关。
